Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.74 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17438818 | 0.85 | OPRM1 (1.00) | OPRM1OPRL1OPRK1SMN1; SMN2CYP2D6 | |
| SCHEMBL17443952 | 0.83 | OPRM1 (0.73) | OPRM1OPRL1OPRK1CYP2D6CYP3A4 | |
| SCHEMBL17438592 | 0.82 | OPRM1 (0.58) | OPRM1OPRL1CYP2D6ITGB3ITGA2B | |
| SCHEMBL17438976 | 0.81 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 | |
| SCHEMBL19137914 | 0.80 | OPRM1 (0.71) | OPRM1OPRL1OPRK1RAB9ASMN1; SMN2 | |
| SCHEMBL17444023 | 0.80 | OPRM1 (0.71) | OPRM1OPRL1OPRK1RAB9ASMN1; SMN2 | |
| SCHEMBL17444025 | 0.80 | OPRM1 (0.71) | OPRM1OPRL1OPRK1RAB9ASMN1; SMN2 | |
| SCHEMBL17439091 | 0.77 | OPRM1 (0.70) | OPRM1OPRL1OPRK1CYP2D6TSHR | |
| SCHEMBL17439114 | 0.75 | OPRM1 (0.54) | OPRM1OPRL1ITGB3ITGA2B | |
| SCHEMBL17438671 | 0.75 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | GRUENENTHAL GMBH (DE) | 2019-02-12 | — | — | US | claimed |
| EP-3169665-A1 | SUBSTITUTED AZA-SPIRO(4.5)DECAN-DERIVATIVES | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | claimed |
| WO-2016008583-A1 | SUBSTITUTED AZA-SPIRO(4.5)DECAN-DERIVATIVES | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.